Avidity Biosciences
RNAM
RNAM was delisted on the 26th of February, 2026.
100 hedge funds and large institutions have $739M invested in Avidity Biosciences in 2021 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 43 increasing their positions, 12 reducing their positions, and 8 closing their positions.
258% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 12
225% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 8
22% more funds holding
Funds holding: 82 → 100 (+18)
7.65% more ownership
Funds ownership: 82.5% → 90.15% (+7.7%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
6% less capital invested
Capital invested by funds: $790M → $739M (-$51.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$19.9M |
| 2 |
State Street
Boston,
Massachusetts
|
+$16.3M |
| 3 |
BlackRock
New York
|
+$16.2M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$11.5M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$9.03M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
-$17.1M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$5.52M |
| 3 |
ACM
Alethea Capital Management
Mercer Island,
Washington
|
-$4.54M |
| 4 |
TG
TCW Group
Los Angeles,
California
|
-$4.13M |
| 5 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$4.02M |
RNAM Hedge Fund Activity: Q1 2021 in Review
100 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Avidity Biosciences (RNAM) for Q1 2021, worth a combined $739M — down 6.5% from $790M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new RNAM positions and 8 closed out — a net gain of 18 holders — while 43 added to existing stakes and 12 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $19.9M. The largest seller was Logos Global Management, exiting entirely with an estimated $17.1M sold.
- 100 institutional investors held Avidity Biosciences (RNAM) as of Q1 2021, up from 82 in Q4 2020.
- Funds reported $739M of Avidity Biosciences stock for Q1 2021, down 6.5% quarter-over-quarter.
- 26 funds opened new Avidity Biosciences positions in Q1 2021 and 8 closed out, a net change of +18 holders.
- The largest Avidity Biosciences buyer in Q1 2021 was T. Rowe Price Associates, an estimated $19.9M added.
- The largest Avidity Biosciences seller in Q1 2021 was Logos Global Management, an estimated $17.1M sold.
Based on aggregated 13F filings for Q1 2021.